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LETTER TO THE EDITOR
Response: The Value of Sentinel Lymph Node Biopsy in
the Management of Head and Neck Melanoma
To the Editor
The possibility that sentinel lymph node biopsy may
increase the risk of in-transit metastases, thereby reducing,
eliminating, or reversing any potential survival advantage
associated with the sentinel lymph node biopsy technique,
is an area of ongoing debate and reflects the letter to the
editor of Dr. Alvarado, Dr. Sondak, and Dr. Leong.
In a review of the literature Thomas calculated a 20.9%
incidence of local or in-transit metastases in those who
underwent complete lymph node dissection because of
tumor-positive sentinel lymph nodes and a 5.7% incidence
in patients who had tumor-negative sentinel lymph nodes
and did not undergo complete lymph node dissection [1].
In a study (N¼ 250) of the Netherlands Cancer Institute
in-transit metastases were found in 23% of the sentinel
lymph node-positive group and in 7% of the sentinel lymph
node-negative group [2]. These percentages are compar-
able with the incidence of in-transit metastases that were
found in the UMCG series (N¼ 300); 20% and 4%,
respectively (P< 0.001) [3].
We agree with our correspondents that a critical
analysis of the data from multicenter studies from both
the United States and Australia, provides compelling
evidence that the sentinel lymph node biopsy procedure
and complete lymph node dissection in sentinel lymph
node-positive patients do not increase the incidence of in-
transit metastases [4,5]. It seems indeed most likely that
in-transit metastasis is the result of inherently adverse
biology rather than mechanical disruption of the proximal
nodal basin caused by either sentinel lymph node biopsy
or subsequent complete lymph node dissection.
With regards to the impact of sentinel lymph node
biopsy on clinical outcome, the authors correctly point
out that the results of the SLN Working Group and
the Multicenter Selective Lymphadenectomy Trial I
(MSLT-I) indicate a significantly higher disease-free
survival rate after immediate complete lymph node dis-
section for occult nodal metastases than delayed com-
plete lymph node dissection for clinical nodal recurrence.
Furthermore, MSLT-I showed a significant higher overall
melanoma-specific survival benefit of early regional
node dissection based on the sentinel node status as well
[6,7].
For staging and assessment of prognosis in primary
melanoma, and for identifying patients who may benefit
from immediate complete lymph node dissection, it
seems justified that sentinel lymph node biopsy becomes
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